Can you build a tolerance to peptides, and does cycling prevent it?

Adaptation can occur, but it depends on the peptide and the effect being measured. Human experiments with continuous GLP-1 exposure show that its slowing of stomach emptying can weaken relatively quickly, a phenomenon called tachyphylaxis. That does not establish that all GLP-1 effects disappear, or that a person’s receptors have broadly “shut down.” Less nausea or a different sensation of fullness is not a direct measurement of receptor function.[1]

A weight plateau is also not proof of complete drug tolerance. It can reflect a new balance between energy intake and expenditure, with the treatment still helping maintain the loss. Continued-treatment trials show that meaningful effects can persist beyond the initial weight-loss period. Cell experiments about receptor internalization cannot, by themselves, tell us whether a scheduled break improves long-term clinical outcomes.[2]

The cited clinical evidence does not establish cycling as a way to prevent tolerance. Withdrawal evidence instead shows a risk of losing the treatment’s benefit: in the STEP 1 extension, participants regained about two-thirds of their prior semaglutide-associated weight loss during the year after treatment and structured lifestyle support ended. Planned pauses therefore should not be presented as a proven receptor-reset strategy.[3]